Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
3.280
+0.010 (0.31%)
At close: Nov 26, 2025, 4:00 PM EST
3.291
+0.011 (0.34%)
After-hours: Nov 26, 2025, 5:57 PM EST
Lipocine Employees
Lipocine had 16 employees as of December 31, 2024. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
$270,168
Profits / Employee
-$342,202
Market Cap
18.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 0 | - |
| Dec 31, 2022 | 17 | 4 | 30.77% |
| Dec 31, 2021 | 13 | 2 | 18.18% |
| Dec 31, 2020 | 11 | -1 | -8.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LPCN News
- 8 days ago - Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 20 days ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 22 days ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire
- 2 months ago - Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 3 months ago - Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 - PRNewsWire
- 4 months ago - Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 - PRNewsWire
- 5 months ago - Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression - PRNewsWire